Sunitinib + GM-CSF + Cyclophosphamide + IMA901
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Renal Cell Carcinoma
Conditions
Metastatic Renal Cell Carcinoma
Trial Timeline
Dec 1, 2010 → Jul 1, 2015
NCT ID
NCT01265901About Sunitinib + GM-CSF + Cyclophosphamide + IMA901
Sunitinib + GM-CSF + Cyclophosphamide + IMA901 is a phase 3 stage product being developed by Immatics for Metastatic Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01265901. Target conditions include Metastatic Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Renal Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01265901 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Renal Cell Carcinoma